Skip to main content

Advertisement

Table 2 Percent change from mean baseline normalized to a scale of ± 4

From: Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Assay Epitope 1 2 3 4
MHC tetramer EBV BMLF1259–267 ≥85.89 ≥171.78 ≥257.67 ≥343.56
  CMVpp65495–503 ≥69.89 ≥138.58 ≥207.87 ≥277.16
  MART126–35 ≥107.29 ≥214.58 ≥321.87 ≥429.16
  Tyrosinase368–376 ≥107.29 ≥214.58 ≥321.87 ≥429.16
  gp100209–217 ≥107.29 ≥214.58 ≥321.87 ≥429.16
IFN-γ ELISPOT EBV BMLF1259–267 ≥246.85 ≥493.7 ≥740.55 ≥987.4
  CMVpp65495–503 ≥192.4 ≥384.8 ≥577.2 ≥769.6
  MART126–35 ≥264.1 ≥528.2 ≥792.3 ≥1,056.4
  Tyrosinase368–376 ≥264.1 ≥528.2 ≥792.3 ≥1,056.4
  gp100209–217 ≥264.1 ≥528.2 ≥792.3 ≥1,056.4
HLA-DR   0 – 50 51 – 100 101 – 150 150 – 200+
CD45RO   0 – 50 51 – 100 101 – 150 150 – 200+
QPCR   0 – 50 51 – 100 101 – 150 150 – 200+
  1. MHC = Major histocompatibility complex; EBV = Epstein-Barr virus; CMV = Cytomegalovirus; MART1 = Melanoma-associated antigen recognized by T cells; IFN-γ = Interferon gamma; ELISPOT = Enzyme-linked immunospot; HLA = Human leukocyte antigen; QPCR = Quantitative polymerase chain reaction.